# PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

> **NCT02867332** · PHASE1 · WITHDRAWN · sponsor: **Peking University**

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** PD-1 Knockout T Cells
- **DRUG:** Cyclophosphamide
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT02867332
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867332, "PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02867332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*